Carl Zeiss Meditec integrates technology with solutions-oriented approach in view
May 1st 2004Carl Zeiss Meditec is generating a lot of noise within the ophthalmic industry. Over the last 2 years, Zeiss Meditec has undergone a transformation from the quiet division of a German technology foundation to becoming one of the leading players in the ophthalmic market.
Meeting secure e-mail requirements just got easier
May 1st 2004Protecting patients' privacy has always been a top priority for physicians and staff alike, but now it is mandatory. By April 14, 2005, practices must have taken the necessary steps to comply with Title II of the Health Insurance Portability and Accountability Act (HIPAA) of 1996, which pertains to privacy of health data.
Reverse mortgage is a possibility for senior homeowners
May 1st 2004Q. Because of the diminished cash flow my retired parents are experiencing, they can not afford to do all the things they like, which they are healthy enough to enjoy. I have heard the term 'reverse mortgage.' Could youexplain how this strategy works?
Intravitreal triamcinolone may be helpful PDT adjunct for AMD
May 1st 2004Fort Lauderdale, FL-Intravitreal triamcinolone may enhance the efficacy of photodynamic therapy (PDT) with verteporfin (Visudyne, QLT Phototherapeutics/Novartis Ophthalmics) and decrease the number of re-treatments for eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according to the preliminary results of an open-label study presented by Daniel B. Roth, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
VIM Trial results favor PDT for small, subfoveal minimally classic,AMD-related CNV
April 27th 2004Verteporfin (Visudyne) photodynamic therapy (PDT) using either a reducedor standard light fluence rate appears to be beneficial for patients withrelatively small, subfoveal minimally classic CNV associated with age-relatedmacular degeneration (AMD), said Philip J. Rosenfeld, MD.
PDT + triamcinolone shows promise as treatment for non-subfoveal CNV
April 27th 2004Short-term results from a small study suggest combined verteporfin (Visudyne,Novartis) photodynamic therapy (PDT) with intravitreal triamcinolone meritsadditional investigation for the treatment of non-subfoveal CNV, said RichardF. Spaide, MD.
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
April 26th 2004One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Imaging helps monitor structural damage over time
April 15th 2004Dorado, Puerto Rico-New imaging technologies for glaucoma allow physicians an objective, reproducible, and more user-friendly approach to documenting structural damage to the optic nerve head and retinal nerve fiber layer (RNFL). This is particularly important because, in the majority of glaucoma patients, structural damage occurs before standard visual field loss, noted David S. Greenfield, MD.
Cataract and refractive surgery outcomes improve with new technology
April 15th 2004The use of wavefront technology and customized ablation to treat aberrations and of the fourth-generation fluoroquinolones to prevent infections were the primary topics of a symposium on new technologies in cataract and refractive surgery held in conjunction with the American Academy of Ophthalmology annual meeting, Anaheim, CA.
FDA ready to set standards for contrast sensitivity testing
April 15th 2004The FDA soon will approve standards for contrast sensitivity testing in clinical trials. The approval is a step that will not only make the administration of this test easier for ophthalmologists but its comparison with clinical trial data and other testing centers simpler and more valuable as well.
ARVO 2004 Glaucoma presentations
April 1st 2004At this year's ARVO meeting, glaucoma specialists can broaden their clinicalknowledge of topics ranging from surgery and wound healing to neuroprotectionto retinal nerve fiber layer imaging. Members of Ophthalmology Times'Editorial Advisory Board reviewed dozens of glaucoma abstracts to be presentedat the meeting. Some of the board's selections are highlighted here.
ARVO 2004 Retina presentations
April 1st 2004Among the 233 sessions dedicated to retina, almost 75 are free papersand symposia sessions. The Editorial Advisory Board of OphthalmologyTimes reviewed the retina abstracts to be presented at this year's meeting.Some of the board's selections are highlighted here.
Pay attention to documentation as audit activity continues
April 1st 2004Dorado, Puerto Rico-Physicians need to take a proactive approach to patient chart documentation as audit activity continues under the Health Care Fraud and Abuse Control Program, established under the Health Insurance Portability and Accountability Act (HIPAA) of 1996, said practice management expert Donna M. McCune, CCS-P, COE.
Used properly, systemic medications effective in uveitis
April 1st 2004Baltimore-The use of systemic medications in uveitis therapy often is associated with superior outcomes, and the best results are likely when physicians adhere to proper dosing techniques and closely monitor patients for side effects, said Douglas A. Jabs, MD, MBA.
Contrast sensitivity testing key to measuring visual function
April 1st 2004New York-Contrast sensitivity testing provides a more comprehensive assessment of vision than visual acuity testing. This testing is especially important when assessing, treating, and following patients who have undergone LASIK or those with age-related macular degeneration (AMD), glaucoma, or cataracts.